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Abstract Endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) is a highly
selective and potent agonist of the W-opioid receptor. To identify
structural attributes unique to this opioid peptide and potential
sites of recognition, a conformational analysis has been
performed using multidimensional NMR and molecular modeling
techniques. The spectroscopic results, derived from experiments
in both DMSO and water, indicate that endomorphin-1 exists in
the cis- and trans-configuration with respect to the Pro-omega
bond in approximately 25% and 75% populations, respectively.
In DMSO, the cis-configuration adopts a compact sandwich
conformation in which the Tyr and Trp aromatic rings pack
against the proline ring, whereas the trans-configuration adopts
an extended conformation. Although non-random structure was
not observed in water, condensed phase molecular dynamics
calculations indicate that trans-isomers dominate the population
in this higher dielectric medium. Structural comparison of the
cis- and trans-configurations with morphine and selective W-
peptide ligands PL-017 and D-TIPP, as well as the N-selective
peptide ligands TIPP (N-antagonist, W-agonist) and DPDPE
were also performed and suggest the trans-isomer is likely the
bioactive form. A hypothesis is proposed to explain W- and N-
selectivity based on the presence of spatially distinct selectivity
pockets among these ligands.
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1. Introduction
Opioid receptors are important targets for pharmacological
interaction in acute pain therapy [1]. Recent work in this area
appears to indicate that the observed e¡ects of many opioid
analgesics are caused by combinations of opioid receptor type
activation [2^5]. To unravel these interactions, detailed struc-
tural models capable of di¡erentiating N, W and U receptor
type selectivity and ultimately, receptor activation vs. inacti-
vation are crucial. Structural models have been generally de-
rived from small molecule opioid receptor agonists and antag-
onists [6,7], and while they have advanced our thinking in this
area, and have shed some light on separation of N binding
from U and W binding [8], they are neither predictive nor
complete. Although the small molecule ligands, e.g. opiate
alkaloids, are less problematic to model, their small physical
size as compared to the endogenous opioid ligands, e.g. enke-
phalins, endomorphins, dynorphins, restricts ligand interac-
tions to a small region of the receptor active site and may
fail to fully address the full complement of interactions re-
sponsible for speci¢c receptor type activation [9,10]. Identi¢-
cation and structural characterization of selective opioid pep-
tide ligands for the N receptor (e.g. DPDPE [11], JOM-13 [12])
and the U receptor (dynorphin [13,14]) have allowed modeling
studies to begin for these types, but to date, few such studies
for W-selective peptide ligands (D-TIPP-NH2) have been re-
ported [15].
Recently, two novel peptides, endomorphin-1 (YPWF-
NH2) and endomorphin-2 (YPFF-NH2) were reported as
the endogenous W receptor ligands [16]. Endomorphin-1 shows
remarkable a⁄nity for the W receptor (360 pM) and selectivity
of 4000- and 15 000-fold for the W receptor over the N and U
receptors, respectively. The availability of the endomorphin
peptides makes possible the comparison with other W-selective
peptides, such as D-TIPP (Y-D-Tic-FF-NH2) [15] and PL-017
(YPF-D-P-NH2) [17]. We have studied the properties of endo-
morphin-1 using NMR spectroscopy and molecular simula-
tions, and the results have been complemented with molecular
comparisons of this peptide with D-TIPP and PL-017. Struc-
tural comparisons with the N-agonist DPDPE [11] and the
dual W-agonist/N-antagonist, TIPP-NH2 [18] have also been
performed to rationalize structure-based selectivities among
these ligands and opioid receptor types.
2. Materials and methods
2.1. Synthesis of endomorphin-1
Endomorphin-1 was synthesized using the Merri¢eld solid-phase
method of peptide synthesis. t-BOC chemistry with HBTU [2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa£uorophosphate]
activation was employed for peptide elongation. The peptide-resins
were treated with 95% HF/5% anisole at 34‡C for 1.5 h to generate
free peptides. The peptide-associated resin complexes were washed
with dimethyl ether to remove the anisole. The peptides were ex-
tracted in 20% HOAc and puri¢ed on two 22.5U250 mm Vydac
C18 columns in tandem (5 Wm particle size, 300 Aî pore size) using
a gradient of 0^27% ‘B’ in 27 min at a £ow rate of 30 ml/min. The ‘A’
bu¡er was 0.1% TFA/water and the ‘B’ bu¡er was 0.1% TFA/aceto-
nitrile. The fractions containing the desired peptide were then com-
bined and lyophilized. The dried peptides were characterized by ana-
lytical RP-HPLC and electrospray MS.
2.2. NMR spectroscopy
All spectra were recorded at 600.13 MHz on a Bruker DMX spec-
trometer. Samples in water included 10% deuterium oxide as the lock
solvent and TSP as the chemical shift reference. Spectra were recorded
at 275 K or 278 K. Sample concentrations used were approximately
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0.6 mM or 3.5 mM. TOCSY spectra were measured using a 50 ms
spin lock (10 000 Hz ¢eld strength) using either DIPSI-2 [19] or
MLEV-17 [20] and magic angle gradient water suppression with the
3-9-19 Watergate sequence [21,22]. Through-space correlations were
detected using both NOESY, [23] ROESY [24] (2550 Hz ¢eld
strength) and o¡-resonance ROESY [25] (10 000 Hz ¢eld strength,
10 000 Hz o¡-resonance) experiments using mixing times ranging
from 150 ms to 250 ms. Water suppression was accomplished using
magic angle gradient 3-9-19 Watergate or low power, continuous
wave pre-saturation. The sample in DMSO-d6 was approximately 7
mM and TMS was used as the chemical shift reference. TOCSY [26]
(10 000 Hz spin lock ¢eld for 60 ms) and NOESY (250 ms mix time)
spectra were recorded at 297 K. All 2D spectra were acquired in the
phase sensitive mode (States-TPPI) and processed using a 90‡ shifted,
squared sine-bell apodization [27].
2.3. Restrained molecular dynamics
Restrained molecular dynamics simulations were conducted using
the Insight II/Discover 95 suite of software. All simulations were
conducted in vacuo using the CFF91 force¢eld3. The NOE distance
data were applied a generic distance constraints using a lower distance
bound of 1.8 Aî , and a force constant value set to 10 kcal/mol Aî 2. No
distance cuto¡s were used; a distance dependent dielectric of 3.5Ur
was used. A 20 ps high temperature molecular dynamics simulations
(700‡C) was used to generate a total of 200 random starting geome-
tries. The random structure were cooled by successive minimizations
with the force¢eld scaled at 0.5 (500 cycles of steepest descents); 0.75
(500 cycles of steepest descents), 1.0 (1000 cycles of steepest descent
followed by 1500 cycles of conjugate gradient minimization; conver-
gence criterion set to 0.1 kcal/Aî .) All g bonds were forced to 180‡ (or
0‡ for the cis-proline isomer) using a force constant of 100 kcal/Aî 2.
Chiral centers were constrained to the starting values.
2.4. Systematic conformational searching
General molecular modeling and conformational analysis was
conducted in Sybyl 6.34. Atomic point charges were calculated using
the Gasteiger-Huºckel method [28^32]. Full geometry optimizations
were done using the Tripos force ¢eld [33,34] with the Powell
minimizer and electrostatics. The following variable parameters were
set: termination_criterion = energy, min_energy_change = 0.00001
kcal/mol, max_iterations = 1 000 000, dielectric_constant = 2.0, dielec-
tric_function=distance. Default settings were used for all other varia-
ble parameters.
Systematic conformational searches were done using the Tripos
force ¢eld with the csearch algorithm, energies, and electrostatics.
All rotatable bonds were searched from 0‡ to 359‡. An angle in-
crement of 10‡ was used for the Tyr i dihedral, 20‡ for the Tic i
dihedral, and 10‡ for all the backbone and sidechain rotatable bonds
in the two Phe residues for a total of 10 rotatable bonds. The follow-
ing variable parameters were set: reference_conformation = zeroed,
van_der_Waals_scaling_factors (general = 0.90, 1^4 = 0.82, hbond =
0.65), energy_cuto¡ = 9999.9 kcal/mol, dielectric_constant = 2.0, di-
electric_function = distance. Default settings were used for all other
variable parameters.
Potential energy surface analyses were done in PESA 1.0 [35]. The
following variable parameters were set: ¢nd minima, neighbors mini-
ma noprint, statistics surface minima. Default settings were used for
all other variable parameters.
Steric and electrostatic CoMFA ¢elds [36^38] were calculated with
the CoMFA regions de¢ned automatically using the molecular vol-
umes option. Default settings were used for all other variable param-
eters. Field correlations were calculated with the QSAR COMFA
FIELD COMPARE command. The correlation coe⁄cients of the
steric and electrostatic ¢elds were summed and the conformer with
the highest value was selected as the most similar. This conformer was
then minimized as described above and was ¢t to trans-endomorphin-
1.
2.5. Molecular dynamics simulations
MD simulations were performed using the Amber 4.1 suite of pro-
grams with the Cornell et al. force ¢eld [39]. Simulations in aqueous
solutions were obtained by placing endomorphin-1 in a box of equi-
librated water and then stripping any water molecule at a distance of
2.0 Aî or less from the peptide. The dimensions of the water box were
46U38U35 for a total of 1647 water molecules. An energy minimized,
extended structure was used as the starting structure. Molecular dy-
namics simulations were conducted at constant temperature and pres-
sure using the Berendsen coupling scheme with a time constant of 0.2
for temperature and pressure regulation. Bond lengths were con-
strained using the SHAKE algorithm and an integration time step
of 2 fs was used. A 10 Aî cuto¡ was used for non-bonded interactions
and the non-bonded pairlist was updated every 50 fs. Equilibrium was
reached after about 600 ps as judged from the rmsd deviation from
the initial structure which rose to 4.5 Aî .
3. Results
NMR experimentation was conducted using standard tech-
niques (see Section 2) in H2O (4‡C) and in DMSO-d6 (25‡C).
A variable temperature study was also conducted in DMSO-
d6 to evaluate internal hydrogen bonding. The 1D spectrum
of endomorphin-1 (Fig. 1) clearly highlights the existence of
cis- and trans-isomer populations.
The relative peak intensities from the 1D spectrum for both
the aqueous and DMSO media indicate that endomorphin-1
resides in 25/75% populations of the cis-trans isomers.
The cis-trans peak assignments were con¢rmed by the char-
acteristic sequential NOEs between the Pro and Tyr residues
[40]. Non-sequential ROESY cross peaks were not observed in
aqueous solution for endomorphin-1.
For the cis-isomer in DMSO (Fig. 2), NOE cross peaks
between Pro and both the Tyr2;6 and Tyr3;5 protons, and
the Trp aromatic protons were observed, and are indicative
of a stabilized packing arrangement of the aromatic side
chains with the proline ring. The trans-isomer also exhibited
some elements of non-random conformation, although the
high degree of overlap caused by the close chemical shifts
observed for TrpL2 and Tyr2;6 (7.060 and 7.055 ppm, respec-
tively) makes unambiguous assignments di⁄cult. NOE cross
peaks between the Tyr2;6 aromatic protons and the Pro N and
L protons suggest that the Tyr may pack against the Pro as in
the case for the cis-isomer. In contrast, no cross peaks impli-
cating a stabilized packing interaction between the Pro and
Trp or between Trp and Phe for the trans-isomer are observ-
ed5. Additionally, the presence of an NOE cross peak between
the Phe aromatic protons and the Pro L protons suggests the
tendency for the trans-isomer to adopt an extended conforma-
tion characterized by alternating sidechains for the Trp and
Phe region. Variable temperature NMR experiments show no
evidence for internal hydrogen bonding for either the cis- or
trans-isomer. Conformational forms characterized by stable
turn conformation in both isomers can therefore be elimi-
nated.
The NMR data yield too few NOE constraints per residue
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for a rigorous structure determination. Nevertheless, applica-
tion of the observed cross peaks via restrained molecular dy-
namics was conducted to obtain plausible ‘NMR structures’
for our modeling studies that re£ect the conformations which
cannot be ruled out by the NMR data. Low energy confor-
mations consistent with the NMR data were determined using
NOE restraints for both the cis- and trans-isomers. A total of
19 NOE restraints from the cis-isomer, and 10 NOE restraints
from the trans isomer were taken from the NOESY spectra.
The restraints were calibrated to internal stationary backbone
proton-proton distances (trans-TyrN-ProL and trans-PheN-
ProL) and are shown in Tables 1 and 2.
High temperature molecular dynamics (see Section 2) was
used to generate a set of diverse starting conformations to
which the NOE constraints were gradually applied. Represen-
tative low energy structures with no NOE violations for the
cis-isomer are shown in Fig. 3. In the overlay, a compact
sandwich conformation is clearly discernible, created by the
packing of Tyr and Trp around the proline residue. Fig. 4
shows a representative low energy structure for the trans-iso-
mer.
4. Discussion
One of the key questions this study raises regards the bio-
active conformation of endomorphin-1. Although the NMR
data point to the existence of two very distinct structures of
this small peptide, it is highly unlikely that both isomers
shown in Figs. 3 and 4 bind the W receptor with high a⁄nity.
In previous work on related peptide structures, cis-isomers
similar to that shown in Fig. 3 have been shown to be struc-
turally important in de¢ning the bioactive conformation; the
YP-Ar motif displayed by endomorphin-1 (where Ar is an
aromatic residue) is also found in immunogenic peptides
from the in£uenza virus hemagglutinin and the insect kinin
neuropeptides [41,42]. NMR studies of those YR-Ar peptides
have shown that the cis-isomer is highly stabilized by the
formation of a reverse turn in solution. The Tyr and Trp
sidechains of endomorphin-1 pack against the proline ring
in a similar fashion as those of the immunogenic peptides,
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Table 1
cis-YPWF-NH2 NOESY analysis. DMSO at 25‡C
NOE pair Estimated distance (Aî )
W2 WK 4.2
W2 PN2 5.0
Y2;6 PN1 4.6
Y3;5 PL 4.6
FNH WL2 3.8
Y2;6 PL 4.6
W2 PL 5.0
WNH PL 3.4
Y2;6 PK 3.8
WNH PK 2.6
Y2;6 YL 2.6
WNH YK 3.8
WL W2 3.8
Y3;5 YL 4.6
FNH WK 2.6
WNH WK 3.8
FNH FL 3.8
FNH PL 5.0
FNH YK 4.6
Fig. 1. 1D NMR spectrum of endomorphin-1 in DMSO-d6 (3.5 mM, 25‡C).
Table 2
trans-YPWF-NH2 NOESY analysis. DMSO at 25‡C
NOE pair Estimated distance (Aî )
F2;6 PL 5.0
Y2;6 PL 4.2
W4 WL 3.4
W4 WK 3.4
Y2;6 PN1 2.6
Y2;6 PN2 3.4
Y2;6 YK 2.6
WNH PL1 3.4
FNH PL1 3.8
FNH PL2 5.0
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but endomorphin-1 is devoid of hydrogen bonds as indicated
by the NMR temperature studies. This may explain why the
cis-isomer is present in 70% for the immunogenic peptides
versus the 25% observed here for endomorphin-1.
The structural properties of cis-endomorphin-1 were further
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Fig. 3. Low energy cis-conformations consistent with DMSO NOE
data. Structures are aligned using an RMS ¢t of the CK carbons.
Fig. 2. NOESY spectrum of YPWF-NH2 in DMSO-d6 (3.5 mM, 25‡C, 250 ms mixing time). Cross peaks corresponding to the cis-isomer are
italicized. Sequential NOEs exhibit from V50:1 to V80:1 signal to noise ratio. All NOEs considered exhibited s 3:1 signal to noise ratio.
Fig. 4. Low energy trans-conformation consistent with DMSO
NMR data. Absence of NOE cross peaks between Pro2 and Trp3 as
well as Trp3 and Phe4 support extended conformation.
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explored using molecular dynamics simulations in water and
in vacuo with varying dielectric constants. In each case, the
simulations failed to reproduce the sidechain packing interac-
tions predicted by our NOE data and observed in published
reports [41,42]. Since the dielectric properties of DMSO and
liquid water are signi¢cantly di¡erent (40 versus 78.5, respec-
tively), this result is not surprising. Temussi et al. have also
reported viscosity e¡ects on the structure of small peptides
[43]. Similar to our results, they observed a pattern of struc-
ture in DMSO and no structure in aqueous mediums. Since
structural elements were observed only in DMSO, which is
not a biologically relevant solvent, and that only 25% of the
peptide population for endomorphin-1 exists in the cis-form,
we conclude that the compact structure observed for the cis-
isomer is an artifact of the solution conditions.
To investigate the signi¢cance of the trans-isomer to peptide
binding, molecular dynamics simulations have also been per-
formed on this conformer in water. An analysis of a 5 ns
trajectory reveals the peptide exists in two stable structural
families separated by a set of rotations about the i (Pro)
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Fig. 5. Timecourse of a 5 ns simulation of solvated endomorphin-1. Equilibration was reached after 600 ps, as monitored by the RMS devia-
tion from the initial structure. a: H-bonding distance between the carboxylic oxygen of Tyr and the amide nitrogen of Phe. b: H-bonding dis-
tance between the carboxylic oxygen of Pro and the terminal amide nitrogen. c^h: Timecourse of the backbone dihedrals.
Table 3
Torsion angles of the NMR and simulated structures of endomorphin-1 and of the peptides used in the structural comparisona
Peptideb X0 X1 X2 Tyr X0 X1 X2
i M1 P i M1 P i M1c P i M1c
cis-Endomorphin-1 NMR structure Pro Trp Phe 139 3176 374 172 33 376 0 348 380 3120 3179
trans-Endomorphin-1 NMR structure Pro Trp Phe 154 364 377 180 33 3106 3179 339 350 112 3179
trans-Endomorphin-1 ‘L-III-like’ structure Pro Trp Phe 120 360 370 330 33 360 330 g 360 d t,g,g3
trans-Endomorphin-1 ‘extended’ structure Pro Trp Phe 150 360 370 150 33 3120 330 g, t 3150 d t,g,g3
trans-PL-017 Pro N-MePhe D-Pro 154 368 374 165 33 3130 63 361 60 114 25
D-TIPP D-Tic Phe Phe 148 359 99 3165 358 58 50 347 348 111 174
L-TIPP-NH2 L-Tic Phe Phe 151 365 395 3174 63 3137 65 355 3153 110 179
aAngles are in degrees.
bPeptides are denoted according to the general sequence Tyr-X0-X1-X2-NH2.
ct = trans (M1 = 180), g+ = gauche+ (M1 = 60), g3 = gauche3 (M1 =360).
dConformations with either i=390 and i=3120 were found.
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and P (Trp) dihedral angles (Fig. 5 and Table 3). One family
of states is similar to the L-III turn and is observed between
0.5 and 1.8 ns and again between 2.5 and 3 ns. During these
intervals in time, Pro is in the K-conformation with hydrogen
bonds occurring between the Tyr-carbonyl and the Phe-NH
groups. An additional hydrogen bond can also form between
the Pro-carbonyl and the terminal amine group in this com-
pact structural form as shown in Fig. 5. After 3 ns, however,
the peptide reverts to an extended form devoid of hydrogen
bonds. This second conformational family is characterized by
having relatively extended dihedral angles of 150‡ and 3120‡
for i (Pro) and P (Trp), respectively.
Although our molecular dynamics time lengths are insu⁄-
cient to determine the statistical probability of these two fam-
ilies occurring, the extended structure is consistent with the
NOE data of the trans-isomer. In comparing the experimental
and calculated structures of trans-endomorphin-1, similar
backbone dihedral angles are evident, but di¡erences are
seen in the sidechain conformations. While the NMR data
are compatible with either the Tyr sidechain packed against
the Pro (M1V3150‡) or away from Pro (M1V360‡), Tyr M1
maintained a gauche (3) (M1 360‡) throughout the simula-
tion.
To settle this apparent inconsistency, we have capitalized on
the observation that many potent N, W and U opioid ligands
possess a tyramine (para-hydroxy phenethylamine) moiety
buried within their molecular framework. In fact, the tyrosine
ring and the positively charged nitrogen are general require-
ments for nearly all of the reported small molecule pharma-
cophores [6]. Therefore, in our comparisons, we require that
the tyramine moiety of the peptide ligands adopt the confor-
mation as de¢ned by the small molecule ligands such as mor-
phine.
Our use of the extended conformation of trans-endomor-
phin-1 for the bioactive conformation becomes justi¢ed when
considering how it overlays with other selective W ligands, PL-
017 and D-TIPP. PL-017, by virtue of its two proline rings and
N-methyl amide, prohibits internal hydrogen bonding, is con-
formationally restricted and is essentially forced to adopt an
extended conformation6;7. Given its restricted conformational
£exibility, it was used as a reference template for an active
analog modeling approach [44]. Complimentary ¢t of valid
trans-endomorphin-1 structures was accomplished with mini-
mal modi¢cation about the Phe residue to align the C-termi-
nus. Alignment of D-TIPP with trans-endomorphin-1 pre-
sented greater di⁄culty because its D-amino acid at the
2-position prevented direct correspondence with endomor-
phin-1 and PL-017 in this region. We therefore conducted a
systematic conformational search of D-TIPP to map its poten-
tial energy surface. A total of 491 local minima were identi¢ed
on the potential energy surface [35] and were aligned to trans-
endomorphin-1 using the ‘tyramine’ moiety and the ring cent-
roids of residues 3 and 4 as pharmacophore features. The D-
TIPP conformer most similar to trans-endomorphin-1 was
then selected by calculating the maximum correlation of their
steric and electrostatic CoMFA ¢elds with those derived for
endomorphin-1 [36^38]. A composite overlay of this D-TIPP
conformer with trans-endomorphin-1 and PL-017 is shown in
Fig. 6.
As seen in Fig. 6, all three peptides are anchored at the
tyrosine residue in accordance with a good ¢t in this region
with small molecule ligands. The hydrophobic groups, Trp3,
Phe3 and Phe3 for endomorphin-1, PL-017 and D-TIPP, re-
spectively, all occupy a region of space which we propose as
the W-selectivity region. This is to be contrasted to the N-se-
lectivity region as identi¢ed by Portoghese et al. [8] and Loew
et al. [6], also indicated in Fig. 6.
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Fig. 7. Comparison of trans-endomorphin-1 ‘extended conformation’
with DPDPE and TIPP-NH2.
6 Note added in proof, see: Wilkes, B.C., Nguyen, T.M.-D., Wel-
trowska, G., Carpenter, K.A., Chung, N.N. and Schiller, P.W. (1998)
J. Peptide Res. 51, 386^394, which was published during the course of
our work.
7 Molecular dynamics simulations in water show that PL-017 adopts
an extended conformation.
Fig. 6. Comparison of trans-endomorphin-1 ‘extended conformation’
with D-TIPP-NH2 and PL-017.
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trans-Endomorphin-1 can also be compared with the NMR
structure of the N-agonist DPDPE, and a low energy confor-
mation of N-antagonist TIPP-NH2. A molecular graphics
overlay is given in Fig. 7. A comparison of the P, i and M1
values for all of the peptides studied are shown in Table 3.
For DPDPE, the W-selectivity region is not occupied, where-
as the N-activity region is. TIPP-NH2 on the other hand pos-
sessed a low energy conformation which is capable of ¢lling
both the W-selectivity pocket, as well as the N-selectivity re-
gion. Interestingly, TIPP-NH2 exhibits a dual W-agonist/N-an-
tagonist pro¢le [18].
Di¡erentiation between the W- and N-selective ligands can be
seen in the region of the C-terminus. Those of W-ligands,
which tend to be amidated, point up and away from the
molecule and occupy a region which is distinctly separated
from that occupied by the N-ligands. On the other hand, the
C-terminus of the N-ligands (which tend to be free acids) oc-
cupies a region slightly lower in the putative receptor pocket.
Schiller et al. have demonstrated that the N-selectivity of
TIPP-NH2 can be increased dramatically if the C-terminal
amide is replaced by the free acid [18]. Our model places
the free acid in the location occupied by the free acid for
the N-selective ligand DPDPE.
5. Conclusion
This study has presented a structural and comparative
study of endomorphin-1 in an e¡ort to understand the struc-
tural attributes that impart opioid binding and selectivity.
Overall, the results provide fairly convincing evidence that
the bioactive form of endomorphin-1 is in the trans, or ex-
tended form. While cis, or compact conformers have been
identi¢ed from NMR studies of related YP-Ar, the results
reported here indicate that such structure is only present in
DMSO, and that endomorphin-1 is devoid of internal hydro-
gen bonds which are a prerequisite for reverse turn or cis
stabilization. It is therefore unlikely that endomorphin-1
adopts a similar cis-conformation. The signi¢cance of the
trans-isomer to peptide binding and selectivity was further
investigated through structural comparisons with two other
W-selective peptides PL-017 and D-TIPP, as well as the N-se-
lective peptide DPDPE. As shown in Fig. 6, alignment of the
Tyr residues of endomorphin-1, PL-017 and D-TIPP, also al-
lows signi¢cant overlap in the aromatic residues £anking Pro.
In terms of the ‘message-address’ concept forwarded by Por-
toghese et al. [45,46], this secondary element may represent
the ‘address’ or site of selectivity for the W-opioid receptor.
This hypothesis is further supported by structural alignments
of endomorphin-1 and the N-agonist DPDPE, which show
little or no overlap between the putative W-selectivity and N-
selectivity regions of these peptides. Perhaps the most provo-
cative result is seen in the structural comparison using the
dual W-agonist/N-antagonist TIPP-NH2. In this case, both
the W and N ‘addresses’, as well as the tyramine moieties or
opioid ‘message’ of endomorphin-1 and DPDPE can be
aligned onto TIPP-NH2 to form a consistent picture relating
structure and selectivity. It is important to point out, however,
that our results do not rule out the existence of other, relevant
conformations of endomorphin-1 to opioid binding, e.g. ex-
tended cis-conformations. Nevertheless, the results and anal-
yses reported here should provide new insight to the develop-
ment of a wide range of experimental and theoretical studies
aimed at understanding the structural basis for ligand recog-
nition and selectivity of opioid receptors, as well as the struc-
ture-function relationships of the endomorphins and other
related ligands. For instance, site directed mutagenesis experi-
ments, coupled with receptor docking studies of trans-endo-
morphin-1, may provide conclusive evidence as to the exis-
tence of a W-opioid ‘address’ that, to date, has escaped
detection. Such information may prove key in designing nov-
el, highly selective W compounds that may have value clinically
and as pharmacological tools.
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